Medicinova Inc. (MNOV) intrinsic value & 10-year financials
Medicinova Inc. (MNOV) has a Graham intrinsic value of $16.28 per share. At $1.42 on Oct 17, 2026, the stock trades 91% below that value. Over the last 10 fiscal years revenue shrank 43.6% a year to $409.7K, with an average return on invested capital of -72.0%.
- Graham intrinsic value
- $16.28
- Share price (Oct 17, 2026)
- $1.42
- Price vs Graham value
- 91% below
- Market cap
- $69.7M
- Revenue (FY2025)
- $409.7K
- Revenue growth (10-yr CAGR)
- -43.6%
- ROIC (10-yr avg)
- -72.0%
- Free cash flow (FY2025)
- -$9.8M
MNOV 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $409.7K | -$12.0M | -$0.24 | -$9.8M | -3242.5% | -114.7% |
| FY2024 | — | -$11.0M | -$0.23 | -$10.6M | — | -105.0% |
| FY2023 | $1.0M | -$8.6M | -$0.17 | -$7.5M | -990.0% | -30.9% |
| FY2022 | — | -$14.1M | -$0.29 | -$12.9M | — | -44.9% |
| FY2021 | $4.0M | -$10.1M | -$0.21 | -$9.4M | -253.0% | -84.3% |
| FY2020 | — | -$13.9M | — | -$10.9M | — | -125.6% |
| FY2019 | — | -$12.9M | — | -$9.1M | — | -124.3% |
| FY2018 | — | -$14.7M | — | -$9.1M | — | -27.9% |
| FY2017 | — | -$11.2M | — | — | — | -30.8% |
| FY2016 | — | -$10.9M | — | -$6.6M | — | -31.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MEDICINOVA INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MEDICINOVA INC has historically struggled to out-earn its cost of capital, averaging just -72.0% ROIC.
MEDICINOVA INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, MEDICINOVA INC is modeled at -43.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $16.28 per share.